1 The British Society for Haematology does not recommend retesting vitamin B 12 levels after treatment has been initiated, and no guidelines address the optimal interval for screening high-risk patients
In the event that impacted product is administered to a patient, there is an increased risk that severe adverse events such as invasive bacterial infection, including bacterial meningitis, septicemia, and limited adverse events such as fever, chills, malaise, and cutaneous abscess may occur
Oral versus intramuscular cobalamin to treat cobalamin deficiency: noninferiority randomised controlled trial, pragmatic and multicenter in the primary healthcare setting (OB12 project)
Always talk to a healthcare provider about your specific situation
How long before I see results from AHK-Cu